Deferasirox

證據等級: L5

預測適應症: 10 個

Deferasirox: From Iron Overload to HIV Infectious Disease

One-Sentence Summary

Deferasirox is an oral iron chelator established for managing chronic iron overload in transfusion-dependent patients (e.g., beta-thalassemia, sickle cell disease). The TxGNN model predicts it may be effective for HIV Infectious Disease, with 0 clinical trials and 2 publications currently supporting this direction — primarily through the hypothesis that iron chelation disrupts HIV Tat-mediated viral transcription.

Quick Overview

Item	Content
Original Indication	Chronic iron overload (no regulatory record captured in current dataset)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.40%
Evidence Level	L4
EU Market Status	Not registered (per current dataset)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Deferasirox is a tridentate oral iron chelator that selectively binds ferric iron (Fe³⁺). Although detailed MOA data is not available in this dataset, the drug’s pharmacological identity is well-established: it reduces labile plasma iron and tissue iron burden by forming stable, soluble iron complexes that are excreted via the feces. It is most commonly used in patients with transfusional hemosiderosis — a complication of repeated blood transfusions in conditions such as beta-thalassemia and myelodysplastic syndromes.

Iron has a multifaceted role in HIV pathogenesis. HIV-1 Tat protein — the viral transactivator essential for LTR-driven transcription — has been shown to accumulate in endolysosomes, where intracellular iron concentration modulates its oligomerization state. One 2021 in vitro study (PMID 34550543) demonstrated that elevated endolysosomal iron increases Tat oligomerization and β-catenin expression, thereby suppressing LTR transactivation. Separately, iron serves as a cofactor for ribonucleotide reductase, which is required for dNTP synthesis during viral replication. These observations collectively raise the hypothesis that iron chelation could interfere with HIV replication at multiple nodes.

However, this mechanistic link remains directionally ambiguous and unvalidated in human subjects. Removing iron could suppress viral replication under some conditions — but may also impair host immune cell function, potentially worsening HIV outcomes. The TxGNN prediction likely reflects iron’s deep integration in the virus–host graph rather than a directly supported clinical hypothesis. No human trials have tested this.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34550543	2021	Basic Science / In Vitro	Journal of Neurovirology	Endolysosomal iron promotes HIV-1 Tat oligomerization and β-catenin expression, suppressing LTR transactivation — mechanistic evidence that iron status modulates HIV Tat activity in neural cells
16529348	2006	Drug Review / Editorial	Journal of the American Pharmacists Association	Narrative overview of deferasirox as a new drug approval; no HIV efficacy data; confirms deferasirox’s class as an oral iron chelator

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence base consists solely of two early-stage publications — one in vitro mechanistic study and one drug review editorial — with no clinical trials and no human data in HIV populations. While the iron–HIV interaction is biologically plausible, the mechanistic direction is unresolved and the safety profile of iron chelation in immunocompromised patients has not been characterized.

To proceed, the following is needed:

Formal MOA documentation (DrugBank or pharmacological literature) confirming iron chelation mechanism
In vitro or animal model studies specifically demonstrating deferasirox suppresses HIV-1 replication at clinically relevant concentrations
Clarification of the directional iron–HIV hypothesis: does lower iron help or harm the host immune response?
Safety data in HIV-infected or immunocompromised populations (renal function, hepatotoxicity, cytopenias)
Recovery of TFDA/EMA regulatory record (SmPC) to identify contraindications relevant to HIV co-morbidities (e.g., renal impairment, concurrent antiretroviral DDI risk)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.